Breast cancer (BC) resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor (ER) signaling, and ways to block ER pathway in these tumors are sought after. We identified the H3K79 methyltransferase DOT1L as a novel cofactor of ER in BC cell chromatin, where the two proteins colocalize to regulate estrogen target gene transcription. DOT1L blockade reduces proliferation of hormone-responsive BC cells in vivo and in vitro, consequent to cell cycle arrest and apoptotic cell death, with widespread effects on ER-dependent gene transcription, including ER and FOXA1 gene silencing. Antiestrogen-resistant BC cells respond to DOT1L inhibition also in mouse xenografts, with reduction in ER levels, H3K79 methylation, and tumor growth. These results indicate that DOT1L is an exploitable epigenetic target for treatment of endocrine therapy–resistant ER-positive BCs.

Inhibition of histone methyltransferase DOT1L silences ER gene and blocks proliferation of antiestrogen-resistant breast cancer cells

Nassa, Giovanni;Salvati, Annamaria;Tarallo, Roberta;Alexandrova, Elena;Memoli, Domenico;Sellitto, Assunta;Rizzo, Francesca;Giurato, Giorgio;Weisz, Alessandro
2019-01-01

Abstract

Breast cancer (BC) resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor (ER) signaling, and ways to block ER pathway in these tumors are sought after. We identified the H3K79 methyltransferase DOT1L as a novel cofactor of ER in BC cell chromatin, where the two proteins colocalize to regulate estrogen target gene transcription. DOT1L blockade reduces proliferation of hormone-responsive BC cells in vivo and in vitro, consequent to cell cycle arrest and apoptotic cell death, with widespread effects on ER-dependent gene transcription, including ER and FOXA1 gene silencing. Antiestrogen-resistant BC cells respond to DOT1L inhibition also in mouse xenografts, with reduction in ER levels, H3K79 methylation, and tumor growth. These results indicate that DOT1L is an exploitable epigenetic target for treatment of endocrine therapy–resistant ER-positive BCs.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11386/4721111
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 38
social impact